Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/Kb transgenic mice

Immunology

Volumn 121, Issue 1, 2007, Pages 105-112

  Zhang, Yuxia ^a,b   Li, Shu ^c   Shan, Ming ^a   Pan, Xuwen ^a   Zhuang, Ke ^c   He, Lihua ^a   Gould, Keith ^d   Tien, Po ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c WUHAN UNIVERSITY   (China)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cytotoxic T lymphocytes; Hepatitis B virus; Human leucocyte antigen A2 single chain trimer; Human leucocyte antigen A2 transgenic mice

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HLA A2 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIGEN PRESENTATION; BETA 2-MICROGLOBULIN; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HEPATITIS B ANTIGENS; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; SPLEEN; TRANSFECTION; VACCINES, DNA; VACCINIA VIRUS;

EID: 34047228603     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02543.x     Document Type: Article

References (29)

1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68.
2. Yang SH, Lee CG, Park SH et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006; 13:1110-17.
3. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174:1565-70.
4. Lohr HF, Gerken G, Schlicht HJ, Meryer zum Buschenfelde KH, Fleischer B. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993; 168:1133-9.
5. Lohr HF, Krug S, Herr W, Weyer S, Schlaak J, Wolfel T, Gerken G, Meyer zum Buschenfelde KH. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver 1998; 18:405-13.
6. Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge. Intervirology 2006; 49:144-51.
7. Li X, Yang X, Li L, Liu H, Liu J. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine 2006; 24:3321-31.
8. Li N, Fan XG, Chen ZH, Zhu C, Liu HB, Huang Y. Inhibition of the hepatitis B virus replication in vitro by an oligodeoxynucleotide containing cytidine-guanosine motifs. Immunol Lett 2006; 102:60-6.
9. Li H, Zhou M, Han J, Zhu X, Dong T, Gao GF, Tien P. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 2005; 174:195-204.
10. Zhao YG, Peng B, Deng H et al. Anti-HBV immune responses in rhesus macaques elicited by electroporation mediated DNA vaccination. Vaccine 2006; 24:897-903.
11. Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, Wu TC, Hung CF. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther 2005; 12:1180-6.
12. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188:1075-82.
13. Webster DP, Dunachie S, McConkey S et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006; 24:3026-34.
14. Ranasinghe C, Medveczky JC, Woltring D et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for highlevel mucosal and systemic immunity against HIV-1. Vaccine 2006; 24:5881-95.
15. Perez-Jimenez E, Kochan G, Gherardi MM, Esteban M. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect 2006; 8:810-22.
16. Gilbert SC, Moorthy VS, Andrews L et al. Synergistic DNAMVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006; 24:4554-61.
17. Smith CL, Dunbar PR, Mirza F et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005; 113: 259-66.
18. Hutchings CL, Gilbert SC, Hill AV, Moore AC. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 2005; 175:599-606.
19. Fang Q, Yang L, Zhu W et al. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 2005; 335:242-51.
20. Tourdot S, Nejmeddine M, Powis SJ, Gould KG. Different MHC class I heavy chains compete with each other for folding independently of beta 2-microglobulin and peptide. J Immunol 2005; 174:925-33.
21. Tourdot S, Gould KG. Competition between MHC class I alleles for cell surface expression alters CTL responses to influenza A virus. J Immunol 2002; 169:5615-21.
22. Hung CF, Calizo R, Tsai YC, He L, Wu TC. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 2006; 25:127-35.
23. Jaramillo A, Narayanan K, Campbell LG et al. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004; 88:29-41.
24. Zi XY, Yao YC, Zhu HY et al. Long-term persistence of hepatitis B surface antigen and antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice. Eur J Immunol 2006; 36:875-86.
25. Stevenson FK, Rice J. Optimizing cancer immunotherapy trials: back to basics. Eur J Immunol 2006; 36:1070-3.
26. Ramage JM, Metheringham R, Moss R, Spendlove I, Rees R, Durrant LG. Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice. Vaccine 2004; 22:1728-31.
27. Firat H, Cochet M, Rohrlich PS, Garcia-Pons F, Darche S, Danos O, Lemonnier FA, Langlade-Demoyen P. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wildtype/ HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int Immunol 2002; 14:925-34.
28. Street MD, Doan T, Herd KA, Tindle RW. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16, E7 protein. Immunology 2002; 106: 526-36.
29. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185:2043-51.